A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report

Payandeh, Mehrdad; Karami, Afshin; Rostom, S.; Karami, Noorodin; Aeinfar, Mehrnoush

doi:10.15419/bmrat.v6i5.544

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, PLPS and MPLPS may respond to a doxorubicin and ifosfamide combination; trabectedin and eribulin are also options for advanced disease. A reduction in the primary tumor and the eradication of lung metastasis were reported in a clinical case of combined PLPS treatment with the multi-kinase inhibitor pazopanib, eribulin and dacarbazine [139]. Significant work remains to be done to develop novel therapies for this disease.…”

Section: Plps and Mplps: No Specific Targetsmentioning

confidence: 99%

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection

Lesovaya,

Fetisov,

Bokhyan

et al. 2024

Cancers

View full text Add to dashboard Cite

Liposarcoma (LPS) is one of the most common adult soft-tissue sarcomas (STS), characterized by a high diversity of histopathological features as well as to a lesser extent by a spectrum of molecular abnormalities. Current targeted therapies for STS do not include a wide range of drugs and surgical resection is the mainstay of treatment for localized disease in all subtypes, while many LPS patients initially present with or ultimately progress to advanced disease that is either unresectable, metastatic or both. The understanding of the molecular characteristics of liposarcoma subtypes is becoming an important option for the detection of new potential targets and development novel, biology-driven therapies for this disease. Innovative therapies have been introduced and they are currently part of preclinical and clinical studies. In this review, we provide an analysis of the molecular genetics of liposarcoma followed by a discussion of the specific epigenetic changes in these malignancies. Then, we summarize the peculiarities of the key signaling cascades involved in the pathogenesis of the disease and possible novel therapeutic approaches based on a better understanding of subtype-specific disease biology. Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.

show abstract

Section: Plps and Mplps: No Specific Targetsmentioning

confidence: 99%